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Abstract 
Received:  19.03.2014  The present work describes the preparation of Perindopril erbumine ethosomes and study of 
effect of alcohol and phospholipid on transdermal delivery. Perindopril erbumine is an ACE 
inhibitor which slowly inhibits the activity of the enzyme ACE, which decreases the production 
of angiotensin II, is being involved in the blood pressure regulation. Perindopril erbumine 
loaded ethanolic Liposomes were prepared by an hot -  cold method using different 
concentrations of Alcohol and Soya lecithin in different ratios and propylene glycol. The 
prepared ethosomal formulations were subjected to Vesicle size analysis, Morphological 
studies, Entrapment efficiency, In vitro release, Stability studies, In vitro permeation study and 
kinetic data analysis. The vesicle size of ethosomes varied between 1.96±0.003 to 4.56±0.008 
µm (Without sonication) and from 1.62±1.31 to 1.99±1.02 µm (With sonication), Entrapment 
efficiency between 43.91±0.57 to 78.04±0.30%. FT-IR, DSC and Zetapotential studies revealed 
the integrity of the drug in the formulations. In vitro release profiles indicated that the highest 
% of drug  release is 95.22±0.35 over period of 24 hrs with 30% alcohol & 2% phospholipid 
(ETH8) compared to other formulations. The in vitro permeation across rat abdominal skin for 
the optimized formulations ETH3 and ETH8 after 24 hrs was found to be 79.63% and 85.33% 
respectively. Stability studies indicated that, the prepared ethosomes remained stable at 
refrigeration (4-8˚C)  and  room  (25±2˚C)  temperature.  The  prepared  ethosomes  showed 
promising results under in vitro conditions. 
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Introduction 
 
Hypertension (HTN) or high blood pressure is a cardiac 
chronic medical condition in which the systemic 
arterial blood pressure is elevated above the normal 
value. The antihypertensive are a class of drugs that are 
used to treat hypertension. There are many classes of 
antihypertensive, which lower blood pressure by 
different means; among the most important and most 
widely used are the thiazide diuretics, the ACE 
inhibitors, the calcium channel blockers, the beta 
blockers, and the angiotensin II receptor antagonists[1]. 
Perindopril Erbumine (Perindopril tert-butylamine) is 
an ACE inhibitor, used in the treatment of hypertension 
and congestive heart failure, perindopril is converted in 
the body into active metabolite perindroprilate. 
Perindopril erbumine shows 65-75% bioavailability but 
presence of food reduces the conversion of perindopril 
to the perindoprilate. According to a previous research, 
the oxidation rate of Perindopril erbumine in dermal 
homogenate is significantly lower than the intestinal 
homogenate because the oxidative product of 
Perindopril erbumine a perindoprilate shows poor 
absorption from the intestine [2]. When administered 
initially Perindopril erbumine causes hypotension, 
which can prove to be harmful in diuretic treated and 
congestive heart failure patients. Persistent hypotension 
may cause some trouble in myocardial  infarction 
patients [3]. Therefore, the use of transdermal drug 
delivery system can reduce the side effects associated DEVELOPMENT AND CHARACTARIZATION OF PERINDOPRIL ERBUMINE LOADED ETHANOLIC 
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with Perindopril erbumine. Ethanolic Liposomal 
carriers, well known for their potential in topical drug 
delivery, have been used to transport perindopril 
erbumine molecule in the skin layer. 
Skin acts as a major target as well as a principal barrier 
for topical/transdermal drug delivery. Despite the many 
advantages of this system, the major obstacle is the low 
diffusion rate of drugs across the corneum stratum. 
Several methods have been tried to increase the 
permeation rate of drugs temporarily. One simple and 
convenient approach is application of drugs in 
formulation with elastic vesicles or skin enhancers. 
Ethosomes have the potential of overcoming the skin 
barrier and have been reported to enhance permeability 
of drug through the stratum corneum barrier.  
Ethosomal carriers are systems containing soft vesicles 
and are composed mainly of phospholipid 
(Phosphotidyl choline; PC), ethanol at relatively high 
concentration and water. Ethosomes penetrate the skin 
and allow enhanced delivery of various compounds to 
the deep strata of the skin or to the systemic circulation 
[4]. 
 
Experiment Details 
 
Materials. Perindopril Erbumine was obtained as gift 
sample from GlenmarkPharmaceuticals Pvt. Ltd, Goa. 
Cholesterol, Soya lecithin, propylene Glycol and 
Alcohol were procured from S.D Fine Chemicals Pvt 
Ltd, Mumbai. 
Methods:  Preparation of Perindopril 
erubumine ethosomes. The ethosomal system of the 
prepared perndopril erubumine comprised of 1-4 % 
phospholipids, 20-40 % ethanol, 0.4 % of perndopril 
erubumine and aqueous phase to 100 % w/w. 
Phospholipid and drug were dissolved in ethanol. In 
this solution double distilled water was added slowly in 
a fine stream with constant mixing at 700 rpm in a 
closed vessel. The temperature was kept to 30°C 
throughout the experiment. The mixing was continued 
for addition of five minutes. The preparation was 
stored at 4°C [5-6]. 
Preparation of Perndopril erubumine liposomes.  
Liposomes were prepared by cast film method. Soya 
phospholipid (2 % w/w) and cholesterol (0.15 % w/w) 
were dissolved in minimum quantity of chloroform in a 
round bottom flask. The organic solvent was removed 
under reduced pressure to form a thin film on the wall 
of the flask. The deposited lipid film was hydrated with 
distilled water containing drug (25 ml) by mechanical 
shaker for 1hour at room temperature. 
Table 1: Composition of different unsonicated ethosomal and liposomal formulations 
Formulation 
Code 
Phospholipid 
(%w/w) 
Ethonal 
(%w/w) 
Propylene Glycol 
(%w/w) 
Cholesterol 
(%w/w) 
Drug 
(%w/w) 
Distilled Water 
(%w/w) 
ETH1  1.0  20  20  --  0.4  q.s 
             
ETH2  2.0  20  20  --  0.4  q.s 
             
ETH3  3.0  20  20  --  0.4  q.s 
ETH4  1.0  30  20  --  0.4  q.s 
             
ETH5  2.0  30  20  --  0.4  q.s 
             
ETH6  3.0  30  20  --  0.4  q.s 
ETH7  1.0  40  20  --  0.4  q.s 
             
ETH8  2.0  40  20  --  0.4  q.s 
             
ETH9  3.0  40  20  --  0.4  q.s 
LPH  2.0  --  20  0.15  0.4  q.s 
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Characterization of ethosomes and liposomes. Size 
and shape analysis.  Microscopic analysis was 
performed to determine the average size of ethosomes 
and liposome. A sample of ethosomes was suitably 
diluted with distilled water in order to observe 
individual vesicle and a drop of diluted suspension was 
put on a glass slide covered with cover slip and 
examined under microscope (magnification15 × 45 X). 
The diameters of 150 vesicles were determined 
randomly using calibrated eyepiece micrometer with 
stage micrometer. The average diameter was calculated 
using the formula: Average diameter ( dav )= nd/n; 
where, n = number of vesicles;  d = diameter of the 
vesicles.  Further analyses of sonicated vesicles were 
done under a special microscope, which is connected 
with software, and photomicrographs were taken under 
400 and 800x magnification. Selected 
photomicrographs were analysed for size analysis by 
using special software “particle size analysis” 
developed by BIOVIS. This special software works on 
images of photomicrographs with standard dimension 
[7]. Surface Morphological study. The morphology of 
vesicles derived from ethosomal preparation was 
studied using Scanning Electron Microcopy. SEM 
revealed that the vesicles formed were spherical, 
smooth, and there was no formation of aggregates. 
Entrapment efficency. The entrapment efficiency of 
Perindopril erbumine  by ethosomal vesicle were 
determined by ultracentrifugation, 10ml of ethosomal 
and liposomal formulation were  vortexed for 2 cycle 
of 5 min with 2 minutes rest between the cycles. 1.5ml 
of each vortexed sample and fresh untreated ethosomal 
formulations were taken into different centrifuge tubes. 
These samples were centrifuged at 20,000 rpm for 3 
hours. The supernatant layer was separated, diluted 
with water and drug concentration was determined at 
206 nm in both vortexed and unvortexed samples. The 
entrapment efficiency was calculated as follows,  % 
Entrapment Efficiency= [Total drug- Free drug / Total 
drug)] x 100.  Zeta potential.  Zeta potential is an 
important and useful indicator of particle surface 
charge, which can be used to predict and control the 
stability. In general, particles could be dispersed stably 
when the absolute value of zeta potential is up to 30mV 
due to the electric repulsion between particles [8]. In 
Vitro  Release.  In vitro release studies on ethosomal 
preparation were performed using Franz-diffusion cell. 
The capacity of receptor compartment was 15 ml. The 
area of donor compartment exposed to receptor 
compartment was 1.43cm2. The dialysis cellophane 
membrane (MMCO14KDC) was mounted between the 
donor and receptor compartment. A weighed amount of 
ethosomal preparation was placed on one side of the 
dialysis membrane. The receptor medium was 
phosphate saline buffer of pH 6.8. The receptor 
compartment was surrounded by a water jacket to 
maintain the temperature at 37±1oC. Heat was 
provided using a thermostatic hot plate with a magnetic 
stirrer. The receptor fluid was stirred by a Teflon-
coated magnetic bead fitted to a magnetic stirrer. At 
each sampling interval, samples were withdrawn and 
were replaced by equal volumes of fresh receptor fluid 
on each occasion. Samples withdrawn were analyzed 
spectrophotometrically at 206 nm [9]. In vitro 
permeation studies.  The permeation of Perindopril 
erbumine from ethosomal formulations was determined 
by using Franz diffusion cell. The shaved abdominal 
skin of mice (0.5±0.1 mm thickness and 3.17 cm2 
exposed surface areas) was mounted on the receptor 
compartment with the stratum corneum side facing 
upwards towards the donor compartment. The receptor 
compartment was ﬁlled with 15 ml of pH 6.8 phosphate 
buffer maintained at 37. 8 ˚C and stirred by a magnetic 
bar at 600 rpm. One ml of ethosomal formulation was 
placed on the skin and the top of the diffusion cell was 
covered with paraffin paper. At appropriate time 
intervals (0.5, 1, 2, 3, 4, 6, 8, 10, 12, 16, 20 and 24 h), 1 
ml aliquots of the receptor medium were withdrawn 
and immediately replaced by an equal volume of fresh 
receptor solution to maintain sink conditions samples 
withdrawn and were analyzed spectrophotometrically 
at 206 nm[10].   Stability Studies.  The ability of 
vesicles to retain the drug (Drug Retention Behaviour) 
was assessed by keeping the ethosomal formulations at 
two different temperature conditions, i.e., Refrigeration 
Temperature (4-80C) & Room Temperature (25±20C). DEVELOPMENT AND CHARACTARIZATION OF PERINDOPRIL ERBUMINE LOADED ETHANOLIC 
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Throughout the study, ethosomal formulations were 
stored in aluminium foil-sealed glass vials. The 
samples were withdrawn at different time intervals 
over a period of 8 weeks and were analysed for 
entrapment effiency, drug content and in vitro release 
[11-12]. 
 
Results and Discussions 
 
Vesicle size analysis.  Results of vesicle size of 
perindopril erbumine ethosomal formulations are 
presented in Table 2, which indicated that vesicle 
formed with 40% alcohol are smaller in size than 
vesicle formed with 20% alcohol and this is due to 
increase in the alcohol content.  
Table 2: Physicochemical charaterization of Perindopril 
erbumine ethosomal and liposomal formulations  (ETH1-
ETH9 & LPH) 
Sr.No  Formulation 
Code 
Vesicle 
Size(µm) 
% Entrapment 
Efficiency 
1  ETH1  2.54±0.03  54.81±0.30 
2  ETH2  3.37±0.10  74.52±0.14 
3  ETH3  4.56±0.08  69.24±0.20 
4  ETH4  1.96±0.03  67.03±0.61 
5  ETH5  2.84±0.04  78.04±0.30 
6  ETH6  3.31±0.01  69.61±1.16 
7  ETH7  1.62± 1.31  68.95±0.57 
8  ETH8  1.99± 1.02  62.01±0.83 
9  ETH9  2.14±0.03  67.79±0.37 
10  LPH  5.21±0.02  49.07±1.56 
It is indicated that increase in alcohol content as well as 
decreased in the concentration of the phospholipid 
content resulting in smaller vesicle size. Size of 
vesicles was reduced when the dispersion was 
sonicated. We explain this by the fact that the increase 
in alcohol concentration reduces the strength of 
vesicular layer due to the perforation which results in 
breakage of larger vesicles to smaller vesicles. The size 
range was found to be 1.62± 1.31 µm to 4.56±0.08µm.  
 
Figure 1: Size distribution of  ETH5 
Vesicle size of liposomal formulation was found to be 
5.21±0.02 µm. Alcohol  used  in  ethosomes  has  a  
great  effect  on  vesicle  size. Vesicles formed from 
different alcohols are of different size and they follow 
the order Ethanol 20%> 30% > 40% of alcohol. 
Surface morphological studies.  Surface 
morphological studies were mainly done using 
scanning electron microscopy (SEM), which indicated 
that vesicle formed in ethosomal formulation was 
spherical, rounded, smooth and there was no formation 
of any aggregates.  
 
Figure 2: Scanning electron micrograph of optimized 
formulation of Perindopril erbumine ethosomes. 
 
Figure 3: Optical photomicrograph of optimized formulation 
of Perindopril erbumine ethomes (ETH8) 
Zeta potential. Zeta potential of optimised formulation 
obtaind from Malvern Instruments Ltd. by using 
Zetasizer instrument was found to be 18.4mV. Thus the 
higher surface charge indicates there is no aggregation 
between the particles.     
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Figure 4: Zeta Potential of optimized formulation of 
Perindopril erbumine ethosomes.  ( ETH8) 
 
Entrapment efficiency (%).  Vesicle entrapment 
efficiency was mainly dependent on the amount of 
phospholipids, forming the bilayers and intrinsic 
properties of  chemical structure, liphophilicity, phase 
transition temperature, alkyl chain length and alcohol 
concentration. It was found that phospholipid content 
having a higher liphophilicity, higher phase transition 
temperature and longer alkyl chain length shows higher 
entrapment. Thus depending upon these properties 
ethosomal formulations prepared with 2-3% 
phospholipids and 30% alcohol shows higher 
entrapment efficiency than other formulations. The 
entrapment efficiency of formulations with 1-2% 
phospholipid and more than 30% of alcohol shows less 
than those of 2-3% of phospholipid and 30% of 
alcohol. This is due to reason that not uniform vesicle 
formation and more permeation of vesicle layer due to 
increased alcohol concentration. Values for entrapment 
efficiency were ranging from 54.81±0.30 to 78.04±0.30 
(%) for different formulations.  
In vitro  release study.  The perindopril erbumine 
ethosomal formulations were prepared by hot method 
incorporating phsopholipid, alcohol and propylene 
glycol in different concentrations and in different 
ratios. In other studies the effect of these phospholipid 
and alcohol on the in vitro release of the drug from 
different ethosomal formulations were carried out in 
phosphate buffer of pH 6.8 by using Franz diffusion 
cell [9]. The cumulative percentage drug release from 
ethoosomal formulations ETH1 to ETH9 was in the 
range of 67.45% to 95.22%. and for LPH it  was 
50.20±0.23%.  The results demonstrate that the 
ethosomes prepared with alcohol 30% and 
phospholipid 2% showed the highest release profile 
when compared to the ethosomes  prepared with 
different concentrations of the same compounds. 
 
Figure 5: In vitro drug  release of Perindopril erbumine 
from different ethosomal formulations. 
This is due to the fact that uniform vesicle formation 
has sufficient penetration through the skin. 
In vitro  permeation study.  Permeation profile of 
perindopril erbumine from optimized ethosomal 
formulations ETH3 and ETH8 through the rat 
abdominal skin after 24 hrs is shown in Fig. 6.  
 
Figure 6: In vitro skin  permeation  profile of perindopril 
erbumine from optimized  ethosomal formulations.  
(ETH3 & ETH8) 
The value for drug permeation (release) for optimized 
formulation ETH3 and ETH8 through the rat 
abdominal skin after 24 hrs was found to be 79.63% 
and 85.20% which is significantly less as compared to 
drug permeated through cellophane membrane i.e. 
86.20%  and 95.22% respectively. The reasons for this 
result is that skin act as a barrier for the transport of the 
drug across skin, fusion of ethosomal vesicle to surface 
of skin and interaction of ethosomal vesicle with 
surface of the skin. 
Stability studies. The stability studies were carried out 
for the optimized formulations (ETH3, ETH8 & LPH) 
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temperature (25±2o C) as per ICH guidelines. The 
optimized ethosomal formulation was evaluated for its 
appearance, entrapment efficiency (%), drug content 
study, and in vitro drug release. No significant changes 
in the appearance, entrapment efficiency (%) and drug 
release study were observed during the stability study. 
The entrapment efficiency (%) of optimized 
formulations (ETH3, ETH8 & LPH) after stability 
studies at refrigeration temperature and at room 
temperature was found to be 
72.18±0.16%,71.84±0.25% 74.89±0.31%, 
73.81±0.38% & 46.83±0.30%,  45.71±0.18% 
respectively. The in vitro drug release of optimised 
formulations (ETH3 ETH8 & LPH)  after stability 
studies at refrigeration temperature and at room 
temperature was found to be 83.57±0.58, 82.65±0.23 & 
92.61±0.31, 91.46±0.35 & 46.23±0.61, 45.22±0.48 
respectively. Similarly in drug content study of 
optimized formulations (ETH3 ETH8 & LPH)  after 
stability studies at refrigeration temperature and at 
room temperature was found to be 98.83±0.12%, 
98.16±0.08% & 98.67±0.14%, 97.93±0.11% & 
98.47±0.12%, 97.53±0.16% respectively. Thus from 
the results it can be observed that no significant 
variations appear in the entrapment efficiency (%) and 
in vitro release values when ethosomal formulations 
were stored at room temperature or refrigerator. This 
indicates that that ethosomal formulation remains fairly 
stable at refrigeration (4-80 C) temperature and room 
temperature (25±20C).  
Table 3: Size Distribution of Perindopril erbumine ethosomal formulation  ETH5 
Size Range 
 
Average 
Size(d) 
 
No. of Vesicles 
(n) 
 
% No. 
of Vesicles 
 
n×d 
Eye piece 
micrometer 
division 
Size in 
micrometer 
0-1  0.00-3.00  1.50  95  63.33  142.50 
1-2  3.00-6.00  4.50  49  32.66  220.50 
2-3  6.00-9.00  7.50  05  03.33  37.50 
3-4  9.00-12.00  11.50  01  00.66  11.50 
4-5  12.00-15.00  13.50  00  00  00 
Total  150    427.00 
*Each value is an average of 3 replications; Average diameter ( dav )= nd/n = 2.84 µm. 
Conclusions 
 
Ethosomal formulations of Perindopril erbumine 
showed promising results under in vitro conditions and 
thus there exist a scope for pharmacokinetic evaluation 
of the developed ethosomal formulations on suitable 
animal models. 
 
Acknowledgements 
 
We are grateful to Glenmark Pharmaceuticals Pvt. Ltd, 
Goa  for gift sample of Perindopril Erbumine  and 
Management of N.E.T Pharmacy College, Raichur for 
providing excellent facility to carry out this work. 
References 
 
[1] K.D Tripathi, Essentials of Medical Pharmacology, New 
Delhi, India, Jaypee Brothers. 449-454, 2003   
[2] Martindale, The complete drug reference. 34
th  Ed. 
Pharmaceutical Press, Great Britain, 980-81, 2005 
[3] X.H Zhou, P.A Li Wan, Stability and in-vitro absorption 
of captopril, enalapril and lisinopril across the rat intestine. 
Biochem Pharmacol.47, 1121-1126, 1994 
[4] E Touitou, B Godin, C Weirs, Enhanced Delivery into 
and across the skin by  Ethosomal carries. Drug Dev. 
Research, 50, 406-415,2000 
[5] D.D Verma, A Fahr, Synergistic penetration effect of 
ethanol and phospholipids on the topical delivery of 
Cyclosporin. A, J. Control Release, 97,55-66, 2004 
[6] E Touitou, Composition of applying active substance to 
or through the skin, US patent. 5,540,934, 1998    
P. Goudanavar, Manjunatha, D. Hiremath, Letters in Applied NanoBioScience, , vol. 3, issue 1, 151-157, 2014 
   
Page | 157  
 
[7] S Jain, R.B Umamaheshwari, P Tripathi, N.K Jain, 
Ultradeformable liposomes: A recent tool for effective 
transdermal drug delivery, Ind J Pharm Sci,65, 223-231, 
2003 
[8] N Dayan, Touitou, Carrier for skin delivery of 
trihexyphenidyl HCl: Ethosomes vs. liposomes E. 
Biomaterials, 21,1879-1885, 2000 
[9]  M. K. Chourasia,  L Kang,  S Y Chan,  Nanosized 
ethosomes bearing ketoprofen for improved transdermal 
delivery, Results in Pharma Sciences, 1(1), 60–67, 2011 
[10] I.A Alsarra, A.A Bosela, S.M Ahmed, G M 
Mahrous,Proniosomes as a drug carrier for transdermal 
delivery of ketorolac, Eur J Pharm and Bio, 59, 485–490, 
2005 
[11] V Dubey, D Dinesh Mishra, N.K Jain, T Dutta, M 
Nahar, D.K Saraf, Dermal and transdermal delivery of an 
anti‐psoriatic agent via ethanolic liposomes, J.  Control. 
Release, 123, 148‐154, 2007 
[12] S Jain, A.K Tiwary, B Sapra, N.K Jain, Formulation and 
evaluation of ethosomes for transdermal delivery of 
lamivudine, AAPS Pharm.Sci.Tech, 8(4), E1‐E9, 2007 
 